Investors sue Inovio Pharmaceuticals over alleged stock price inflation from false statements.

Levi & Korsinsky, LLP is representing investors in a class action lawsuit against Inovio Pharmaceuticals, alleging that the company and certain officers made false or misleading statements from October 2023 to December 2025. The lawsuit claims these misrepresentations about device manufacturing and FDA regulatory pathways artificially inflated Inovio's stock price, which traded on the efficient NASDAQ market. The case relies on the fraud-on-the-market doctrine, allowing investors to presume reliance on the stock price reflecting all public information. Investors interested in joining the class action must act before the April 7, 2026 deadline for lead plaintiff applications.